
Opinion|Videos|June 16, 2025
Improving diversity in future clinical trials for mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Enhancing diversity in mHSPC clinical trials requires community outreach, collaboration, and accessible care for underrepresented populations.
Advertisement
Episodes in this series

Improving Clinical Trial Diversity
Key Themes:
- A multistakeholder approach is required (patients, communities, clinicians, payers, industry).
- Community outreach initiatives are essential for building trust.
- A comprehensive approach is needed to address the barriers to participation.
- Bring clinical trial access directly into communities of color.
Key Points for Physicians:
- Support or participate in community outreach programs.
- Address practical barriers to clinical trial participation with patients.
- Consider geographical and logistical factors when referring patients to trials.
- Recognize the importance of building trust through community engagement.
Notable Insights: Creating direct conduits to high-quality care through community-based initiatives represents a practical strategy for improving trial diversity and addressing historical mistrust.
Clinical Significance: Systematic approaches to improving trial diversity are essential for generating evidence applicable to all patient populations and addressing historical health care disparities.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
TULSA preserves penile length vs robotic prostatectomy in CAPTAIN trial
2
KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM
3
FDA grants priority review to talazoparib plus enzalutamide for HRR gene-altered mCSPC
4
The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD
5











